Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81018 | 0.91 | ALDH1A1 (0.35) | ALDH1A1HPGDKDM4ETYMSCYP1A2 | |
| SCHEMBL80696 | 0.89 | MLNR (0.30) | — | |
| SCHEMBL12268987 | 0.89 | TYMS (0.32) | ALDH1A1HPGDKDM4ETYMSHSD17B10 | |
| SCHEMBL80637 | 0.88 | CRHBP (0.39) | ALDH1A1HPGDKDM4ECYP1A2HSD17B10 | |
| SCHEMBL12268957 | 0.87 | — | — | |
| SCHEMBL81115 | 0.86 | KDM4E (0.33) | ALDH1A1HPGDKDM4EMAPK3MAPK1 | |
| SCHEMBL12127194 | 0.84 | CRHBP (0.42) | ALDH1A1HPGDKDM4ETYMSCYP1A2 | |
| SCHEMBL12127191 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4ETYMSCYP1A2 | |
| SCHEMBL81932 | 0.81 | ALDH1A1 (0.33) | ALDH1A1HPGDKDM4ETHRBHSD17B10 | |
| SCHEMBL12202320 | 0.81 | ENPP1 (0.32) | ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129899-B1 | Azafluorene derivative and organic light-emitting device using the derivative | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129899-B1 | Azafluorene derivative and organic light-emitting device using the derivative | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20120049176-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120049176-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-8110685-B2 | Efficient, durable electron transport layers; low driving voltage; simple, low cost production | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110685-B2 | Efficient, durable electron transport layers; low driving voltage; simple, low cost production | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | AZI2, CYP1A2, CYP2C19 | ALDH1A1 21/4885HPGD 1428/4885KDM4E 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.